Clinical Trials Search Tool

A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis

Disease/Condition: Atopic Dermatitis

Location: Gresham

Ages: 6-17 years of age and >18

Enrollment Opens: 04-08-2021

Enrollment Closes: TBD


This is a Phase 3, parallel group, double blind, vehicle-controlled study in
which ARQ-151 cream 0.15% or vehicle is applied QD for 4 weeks to
subjects 6 years of age and older with mild to moderate atopic dermatitis.

Study ID: ARQ-151-311

To Enroll: Contact Cyn3rgy Research at; 503-907-2179 ext. 4 or visit us on the web at

Posted by: Cyn3rgy Research |